



## Moderna to Host Manufacturing & Digital Day on March 4, 2020

February 26, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a Manufacturing & Digital Day for analysts and investors at 1:00 p.m. ET on Wednesday, March 4 at the Company's manufacturing facility in Norwood, Massachusetts.

Moderna's Manufacturing & Digital Day will include presentations from Stéphane Bancel, Chief Executive Officer; Juan Andres, Chief Technical Operations and Quality Officer; Marcello Damiani, Chief Digital and Operational Excellence Officer and key opinion leaders with a focus on the Company's manufacturing and digital efforts.

A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at [investors.modernatx.com](https://investors.modernatx.com). A replay of the webcast will be archived on Moderna's website for 30 days following the presentation.

### About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators. Moderna has 24 mRNA development candidates in its portfolio across all modalities, with 12 in clinical studies. Four of these programs are in or preparing for Phase 2 studies and the Company is preparing for its first Phase 3 study.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. (Nasdaq: AZN) and Merck, Inc. (Nasdaq: MRK), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by *Science* for the past five years.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200226005810/en/): <https://www.businesswire.com/news/home/20200226005810/en/>

### Investors:

Lavina Talukdar  
Head of Investor Relations  
617-209-5834  
[Lavina.Talukdar@modernatx.com](mailto:Lavina.Talukdar@modernatx.com)

Source: Moderna, Inc.

### Investors:

Lavina Talukdar  
Head of Investor Relations  
617-209-5834  
[Lavina.Talukdar@modernatx.com](mailto:Lavina.Talukdar@modernatx.com)